At DermTech, we are developing gene expression assays to identify cytokine inflammatory profiles that assist clinicians in guiding therapy.
Similar to our skin cancer products, these gene expression assays can be analyzed from samples collected using our Adhesive Skin Collection Kit.
Inflammatory diseases of the skin such as psoriasis, atopic dermatitis, and lupus are caused by autoimmune responses that release numerous cytokines in the skin leading to the inflamed lesions. There are a number of biologic drugs currently approved, and a plethora of drugs in development, that target specific cytokines to mitigate the diseases. Changes in gene expression can be used to identify patients with a specific cytokine profile that may respond to a particular drug therapy. These gene expression changes can be used to monitor response to a chosen therapy and potentially predict flare-ups.

We measure non-invasive gene expression changes of the inflammatory skin conditions that can be used to facilitate drug development, as a biomarker for clinical trial endpoints, and to assess more broadly the cytokine status of a patient’s skin.

For more information, visit our Collaborations page.